Table 2.
Patient characteristics and clinical data of the 60 patients
| Characteristic | Value |
|---|---|
| Sex | |
| Female | 26 (43.3) |
| Male | 34 (56.7) |
| Mean age (years) ± standard deviation | 48.4 ± 11.9 |
| Age range (years) | 21.1–76.4 |
| Age interquartile range (years) | 40.0–57.9 |
| WHO classification | |
| Astrocytoma, WHO grade 3, IDH mutant | 35 (58.3) |
| Oligodendroglioma, WHO grade 3, IDH mutant, 1p19q codeleted | 25 (41.7) |
| Recurrence of the glioma WHO grade 3 | 34 (56.7) |
| Astrocytoma, WHO grade 3, IDH mutant | 20 (58.8) |
| Oligodendroglioma, WHO grade 3, IDH mutant, 1p19q codeleted | 14 (41.2) |
| Mean time to radiological recurrence after resection (months) | 34.8 ± 27.5 |
| Astrocytoma, WHO grade 3, IDH mutant | 29.8 ± 24.3 |
| Oligodendroglioma, WHO grade 3, IDH mutant, 1p19q codeleted | 41.8 ± 31.1 |
| Range of time to radiological recurrence after resection (months) | 9.1–98.4 |
| Astrocytoma, WHO grade 3, IDH mutant | 9.1–94.3 |
| Oligodendroglioma, WHO grade 3, IDH mutant, 1p19q codeleted | 10.6–98.4 |
| Treatment of the recurrent WHO grade 3 glioma | |
| Repeat craniotomy | 20 (58.8) |
| Repeat radiation therapy or repeat combined radio-chemotherapy | 6 (17.7) |
| Temozolomide rechallenge | 4 (11.8) |
| Second line monotherapy with Bevacizumab | 3 (8.8) |
| Second line monotherapy with Nivolumab | 1 (2.9) |
| Malignant transformation to glioblastoma WHO grade 4 at recurrence | 7 (11.7) |
| Initial astrocytoma, WHO grade 3, IDH mutant | 7 (100) |
Unless otherwise specified, data are numbers of patients, with percentages in parentheses. The values for the World Health Organization (WHO) classification listed here are based on results of fluorescence in situ hybridization testing for 1p/19q assignment. IDH, isocitrate dehydrogenase